Technical University of Denmark



Retrospective community based explorative study on Cisplatin-based adjuvant chemotherapy vs. surgery only in completely resected stage IB non-small cell lung cancer (NSCLC)

Wallerek, Sandra ; Græsbøll, Kaare; Sørensen, Jens Benn

Publication date: 2014

Document Version Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

Wallerek, S., Græsbøll, K., & Sørensen, J. B. (2014). Retrospective community based explorative study on Cisplatin-based adjuvant chemotherapy vs. surgery only in completely resected stage IB non-small cell lung cancer (NSCLC). Poster session presented at 39th ESMO Congress (ESMO 2014), Madrid, Spain.

DTU Library Technical Information Center of Denmark

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.

- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Rigshospitalet

Retrospective community based explorative study on Cisplatin-based adjuvant chemotherapy vs. surgery only in completely resected stage IB non-small cell lung cancer (NSCLC).

0.8

0.6

0.4

0.2

0.0

0.8

nate 0.6

Sun 0.4

0.2

0.0

S

Background

The benefit of adjuvant chemotherapy (ACT) following complete surgery in NSCLC stage IB is not fully clarified. **ACT** in this situation is currently considered optional (ESMO guidelines).

Aim

- Examine a consecutive group of unselected completely resected NSCLC stage IB patients who either received adjuvant chemotherapy or surgical resection only
- compare overall survival (OS) and disease free survival (DFS) between the two groups

Methods

- Patients underwent complete radical surgery, 2005-2012
- All patients were considered fit for ACT with cisplatin and vinorelbine were offered adjuvant tretment.
- Some pts decided to receive ACT creating the proband group (PG)
- Other patients declined being the control group (CG)
- 63 variables were collected from medical and surgical records.
- Co-morbidity was scored according to Charlson's comorbidity score (CCMS).
- OS and DFS were calculated using Kaplan-Meier plots A multivariate Cox regression analysis was performed to explore on predictors for outcome.





Department of Oncology

Sandra Wallerek, MD¹, Kaare Græsbøll, PhD², Jens Benn Sørensen, MD, DMSc¹ ¹Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark.


Results


- Totally 184 pts were reviewed, patient characteristics presented in table 1.
- The patients in the CG were older (p<0.001), had higher CCMS (p<0.001), and had more pts with pleural invasion (p=0.028) than the PG group.
- OS: 5-year OS was 80 % for PG vs. 59 % in CG, p: 0.03
- DFS: 5-year DFS in PG was 73 % and 54 % in CG, p=0.024.
- The Cox regression analysis, table 2 revealed that ACT (p=0.02), low **CCS (p=0.003) and low** performance status (p=0.035) were independent significant prognostic factors regarding better OS.

Conclusions

Patients who decided to receive ACT were younger and had lower CCS. ACT was an independent prognostic factor and patients receiving ACT benefitted significantly with respect to both DFS and OS when compared to controls without ACT.

OF HEALTH AND MEDICAL SCIENCES UNIVERSITY OF COPENHAGEN





anate	setting	
	p-value	HR (95 % CI)
	0.02	0.33 (0.13-0.84)
	0.003	1.31 (1.09-1.56)
	0.035	1.92 (1.05-3.52)
	p-value	HR (95 % CI)
	0.026	0.49 (0.26-0.92)
	0.007	1.23 (1.06-1.43)

Proband group	Control group	p-value
n= 74 (%)	n= 110 (%)	
64 (40-78)	68 (44-81)	<0.001
45 (60)	63 (57)	0.65
29 (40)	47 (43)	0.63
		0.13
31 (42)	53 (48)	
18 (24)	49 (45)	
	2 (2)	
25 (34)	6 (5)	
		0.67
50 (68)	77 (70)	
19 (25)	28 (25)	
5 (7)	5 (5)	
		0.62
52 (70)	74 (67)	
16 (22)	23 (21)	
6 (8)	13 (12)	
	10 (12)	
33 (7-90)	32 (8-90)	0.25
		0.20
		< 0.001
30 (41)	23 (21)	
35 (47)	77 (70)	
1 (1)	10 (9)	
8 (11)		
		0.028
23 (31)	18 (16)	0.020
47 (64)	87 (79)	
3 (4)	5 (5)	
1 (1)		
- (-)		

* Corresponding author: sandra.wallerek.01@regionh.dk